Clinical trials
Completed Observational trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
523 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 5 |
| 2005 | 2 |
| 2006 | 8 |
| 2007 | 11 |
| 2008 | 12 |
| 2009 | 15 |
| 2010 | 26 |
| 2011 | 19 |
| 2012 | 23 |
| 2013 | 23 |
| 2014 | 27 |
| 2015 | 27 |
| 2016 | 21 |
| 2017 | 30 |
| 2018 | 42 |
| 2019 | 40 |
| 2020 | 63 |
| 2021 | 47 |
| 2022 | 32 |
| 2023 | 23 |
| 2024 | 18 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 523 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 53 |
| Bayer | 40 |
| I.M. Sechenov First Moscow State Medical University | 22 |
| Pirogov Russian National Research Medical University | 16 |
| Servier Russia | 13 |
| AbbVie | 12 |
| Abbott | 12 |
| Ipsen | 12 |
| Boehringer Ingelheim | 11 |
| Tomsk National Research Medical Center of the Russian Academy of Sciences | 11 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 32 |
| Atrial Fibrillation | 24 |
| Diabetes Mellitus, Type 2 | 24 |
| Hypertension | 23 |
| Diabetes Mellitus | 22 |
| Pulmonary Disease, Chronic Obstructive | 20 |
| Stroke | 20 |
| Cardiovascular Diseases | 15 |
| Coronary Artery Disease | 15 |
| Heart Failure | 12 |
Trials
Showing 1 to 25 of 523. Each trial links to its page on Pharma Observatory.
423 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.